Molbio Diagnostics Q1 FY27 Income at ₹411.5 Cr, EBITDA ₹103.7 Cr vs Loss in Q1 FY26
Molbio Diagnostics reported Q1 FY27 total income of ₹411.5 crore and EBITDA of ₹103.7 crore, a significant turnaround from a loss in Q1 FY26. PAT was ₹52.7 crore. This growth was driven by test-kit consumption. Export orders of ₹57 crore were deferred and recognized in Q1 FY27. The company is focusing on scaling up, R&D, and international expansion.
The announcement details a substantial financial turnaround with significant growth in total income and profitability, moving from losses to profits. This directly impacts investor perception and the company's financial standing. The commentary also highlights strategic initiatives and future growth drivers.
The company reported a significant improvement in financial performance, turning losses into profits and showing strong revenue growth compared to the previous year's quarter. The management commentary also expresses optimism about the company's transition as a listed entity and its future growth prospects.
Molbio Diagnostics Limited has announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a Total Income of ₹411.5 crore for Q1 FY27, a significant increase from a loss of ₹14.5 crore in Q1 FY26. EBITDA stood at ₹103.7 crore in Q1 FY27, compared to a loss of ₹14.5 crore in the prior year's quarter. The company's PAT was ₹52.7 crore with a PAT margin of 12.8% in Q1 FY27, a substantial improvement from a loss of ₹23.9 crore in Q1 FY26.
The management commentary highlighted that FY27 is a milestone year as the company transitions to a listed entity. The strong performance in Q1 FY27 was driven by healthy growth across revenue and profitability. The company noted that its business has a non-linear revenue profile, and performance should be assessed on a full-year basis. Export orders amounting to approximately ₹57 crore, pertaining to Q4 FY26, were deferred due to the situation in the Gulf and were recognized in Q1 FY27. Growth continues to be led by test-kit consumption across the 12,500+ Truenat® devices sold in over 90 countries. The company has capacity headroom for devices and test kits, with FY26 utilization at 42% and 58% respectively, positioning it for scale-up without immediate capex. The pipeline of 34 additional assays across 22 diseases is on track, aiming to expand into oncology and non-communicable diseases. Internationally, Molbio is expanding its presence in Africa and Southeast Asia, entering Latin America, and progressing regulatory pathways in developed markets, including CE-IVDR for its CTNG Test.
Following its listing on August 17, 2026, the deployment of net issue proceeds is underway for capex in automation and its R&D facility in Bengaluru. The company remains focused on disciplined execution, sustained R&D intensity, and improving cash flow quality.
What to do with a filing like this
Molbio Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Molbio Diagnostics Limited. Read the original for the full detail.